Jean-Pierre Droz

Dr. Jean-Pierre Droz


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2010 in BJU International
Verified
Journal Article
Open access
PDF file
JDJean-Pierre Droz
Jean-Pierre Droz
LBLodovico Balducci
Lodovico Balducci
MBMichel Bolla
Michel Bolla
MEMark Emberton
Mark Emberton
JFJohn M. Fitzpatrick
John M. Fitzpatrick
CSCora N. Sternberg
Cora N. Sternberg
Prostate cancer is the most prevalent cancer in men and predominantly affects older men (aged ≥70 years). The median age at diagnosis is 68 years; overall, two‐thirds of prostate cancer‐related deaths occur in men aged ≥75 years. With the exponential ageing of the population and the increasing life‐expectancy in developed countries, the burden of prostate cancer is expected to increase dramatically in the future. To date, no specific guidelines on the management of prostate cancer in older men have been published. The International Society of Geriatric Oncology (SIOG) conducted a systematic bibliographic search based on screening, diagnostic procedures and treatment options for localized and advanced prostate cancer, to develop a proposal for recommendations that should provide the highest standard of care for older men with prostate cancer. The consensus of the SIOG Prostate Cancer Task Force is that older men with prostate cancer should be managed according to their individual health status, which is mainly driven by the severity of associated comorbid conditions, and not according to chronological age. Existing international recommendations (European Association of Urology, National Comprehensive Cancer Network, and American Urological Association) are the backbone for localized and advanced prostate cancer treatment, but need to be adapted to patient health status. Based on a rapid and simple evaluation, patients can be classified into four different groups: 1, ‘Healthy’ patients (controlled comorbidity, fully independent in daily living activities, no malnutrition) should receive the same treatment as younger patients; 2, ‘Vulnerable’ patients (reversible impairment) should receive standard treatment after medical intervention; 3, ‘Frail’ patients (irreversible impairment) should receive adapted treatment; 4, Patients who are ‘too sick’ with ‘terminal illness’ should receive only symptomatic palliative treatment.

1 August 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
JDJean-Pierre Droz
Jean-Pierre Droz
MAMatti Aapro
Matti Aapro
LBLodovico Balducci
Lodovico Balducci
HBHelen Boyle
Helen Boyle
TBThomas Van Den Broeck
Thomas Van Den Broeck
TSToru Sugihara
Toru Sugihara

1 October 2017 in European Urology
Verified
Journal Article
Closed access
JDJean-Pierre Droz
Jean-Pierre Droz
GAGilles Albrand
Gilles Albrand
SGSilke Gillessen
Silke Gillessen
SHSimon Hughes
Simon Hughes
NMNicolas Mottet
Nicolas Mottet
MAMatti Aapro
Matti Aapro

1 January 2010 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
JDJean-Pierre Droz
Jean-Pierre Droz
LBLodovico Balducci
Lodovico Balducci
MBMichel Bolla
Michel Bolla
MEMark Emberton
Mark Emberton
JFJohn M. Fitzpatrick
John M. Fitzpatrick
CSCora N. Sternberg
Cora N. Sternberg

28 February 2008 in BJU International
Verified
Journal Article
Closed access
PDF file
JDJean-Pierre Droz
Jean-Pierre Droz
ACAgnieska Chaladaj
Agnieska Chaladaj

1 May 2016 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
JDJean-Pierre Droz
Jean-Pierre Droz
EEEleni Efstathiou
Eleni Efstathiou
AYAsif Yildirim
Asif Yildirim
PCPaula Cabrera
Paula Cabrera
CKChoung Soo Kim
Choung Soo Kim
HӦHaluk Ӧzen
Haluk Ӧzen